Pravastatin inhibits carboxymethyllysine-induced monocyte chemoattractant protein 1 expression in podocytes via prevention of signalling events

Nephron - Experimental Nephrology

Volumn 106, Issue 1, 2007, Pages

  Gu, Leyi ^a   Ni, Zhaohui ^a   Qian, Jiaqi ^a   Tomino, Yasuhiko ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

Monocyte chemoattractant protein 1; Podocyte; Signal transduction; Statin

Indexed keywords

CARBOXYMETHYLLYSINE; DICHLOROFLUORESCEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE DERIVATIVE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; CHEMOKINE CCL2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; GENE EXPRESSION; LYSINE; MICE; PODOCYTES; PRAVASTATIN; SIGNAL TRANSDUCTION;

EID: 34247877630     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100498     Document Type: Article

References (39)

1. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH, Tesch GH: Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004;65:116-128.
2. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH: Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006;69:73-80.
3. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Makita Z: Advanced glycation end product-inducted apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human cultured mesangial cells. J Biol Chem 2002;277:20309-20315.
4. Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Hyodo N, Suzuki S, Miura S: Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrol Dial Transplant 2005;20:1573-1581.
5. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM: RAGE drives the development of glomerulosclerosis and implicates podocytes activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162:1123-1137.
6. Tanji N, Markowitz GS, Fu C, et al: The expression of advanced glycation end-products and their cellular receptor RAGE in diabetic nephropathy and non-diabetic renal disease. J Am Soc Nephrol 2000;11:1656-1666.
7. Gu L, Hagiwara S, Fan Q, Tanimoto M, Kobata M, Yamashita M, Nishitani T, Gohda T, Ni Z, Qian J, Horikoshi S, Tomino Y: Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006;21:299-313.
8. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41:565-570.
9. Kano K, Nishikura K, Yamada Y, Arisaka O: No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria. Clin Nephrol 2005;63:74-79.
10. Usui H, Shikata K, Matsuda M, Okada S, Ogawa D, Yamashita T, Hida K, Satoh M, Wada J, Makino H: HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 2003;18:265-272.
11. Danesh FR, Kanwar YS: Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J 2004;18:805-815.
12. Faggiotto A, Paoletti R: Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension 1999;34:987-996.
13. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-1650.
14. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar YS: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci USA 2002;99:8301-8305.
15. Martinez-Gonzalez J, Alfon J, Berrozpe M, Badimon L: HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 2001;159:27-33.
16. Nishimura M, Tanaka T, Yasuda T, Kurakata S, Kitagawa M, Yamada K, Saito Y, Hirai A: Effect of pravastatin on type IV collagen secretion and mesangial cell proliferation. Kidney Int 1999;56:S97-S100.
17. Yokota T, Utsunomiya K, Murakawa Y, Kurata H, Tajima N: Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy. Kidney Int 1999;56:S178-S181.
18. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N, Koide H: Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 2002;17:798-802.
19. Blanco S, Vaquero M, Gomez-Guerrero C, Lopez D, Eqido J, Romero R: Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity and mild hypertension. Am J Hypertens 2005;18:557-565.
20. Shibata S, Nagase M, Fujita T: Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive rho signalling. J Am Soc Nephrol 2006;17:754-764.
21. Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K: Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 2003;46:845-851.
22. Mundel P, Reiser J, Kriz W: Induction of differentiation in cultured rat and human podocytes. J Am Soc Nephrol 1997;8:697-705.
23. Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005;54:1626-1634.
24. Huber TB, Reinhardt HC, Exner M, Burger JA, Kerjaschki D, Saleem MA, Pavenstadt H: Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol 2002;168:6244-6252.
25. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA, Mundel P: Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004;113:1390-1397.
26. Han SY, So Ga, Jee YH, Han KH, Kang YS, Kim HK, Kang SW, Han DS, Han JY, Cha DR: Effect of retinoic acid in experimental diabetic nephropathy. Immunol Cell Biol 2004;82:568-576.
27. Viedt C, Dechend R, Fei J, Hansch GM, Kreuzer J, Orth SR: MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-κB and activating protein-1. J Am Soc Nephrol 2002;13:1534-1547.
28. Stoll LL, McCormick ML, Denning GM, Weintraub NL: Antioxidant effects of statins. Drugs Today 2004;40:975-990.
29. Susztak K, Raff AC, Schiffer M, Bottinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006;55:225-233.
30. Bai Y, Wang L, Li Y, Liu S, Li J, Wang H, Huang H: High ambient glucose levels modulate the production of MMP-9 and α5(IV) collagen by cultured podocytes. Cell Physiol Biochem 2006;17:57-68.
31. Hoshi S, Nomoto K, Kuromitsu J, Tomari S, Nagata M: High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem Biophys Res Commun 2002;290:177-184.
32. Flannery PJ, Spurney RF: Transactivation of the epidermal growth factor receptor by angiotensin II in glomerular podocytes. Nephron Exp Nephrol 2006;103:e109-e118.
33. Qin J, Zhang Z, Liu J, Sun L, Hu L, Cooper ME, Cao Z: Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int 2003;64:565-571.
34. Van Aelst L, D'Souza-Schorey C: Rho GT-Pases and signalling networks. Genes Dev 1997;11:2295-2322.
35. Adamson P, Marshall CJ, Hall A, Tilbrook PA: Post-translational modifications of p21rho protein. J Biol Chem 1992;267:20033-20038.
36. Siebenlist U, Franzoso G, Brown K: Structure, regulation and function of NF-κB. Annu Rev Cell Biol 1994;10:405-455.
37. Suske G: The Sp-family of transcription factors. Gene 1999;238:291-300.
38. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Bottinger EP: Apoptosis in podocytes induced by TGF-β and Smad7. J Clin Invest 2001;108:807-816.
39. Ross MJ, Martinka S, D'Agati VD, Bruggeman LA: NF-κB regulates Fas-mediated apoptosis in HIV-associated nephropathy. J Am Soc Nephrol 2005;16:2403-2411.